TABLE 1. Summary of programmatic data on viral load testing,* proxy viral load coverage,† and viral load suppression,§ by age group, sex, and subpopulation — worldwide, fiscal years 2015–2022¶.
| Characteristic (program fiscal years, 2015–2022)¶ | Baseline programmatic data** |
Programmatic data from September 30, 2022 |
Change§§ in VL proxy coverage, baseline–2022, % | Change¶¶ in VL suppression, baseline–2022, % | ||||
|---|---|---|---|---|---|---|---|---|
| No. of eligible†† persons receiving VL test/total eligible persons | VL proxy coverage rate, % | VL suppression rate, % | No. of eligible†† persons receiving VL test/total eligible persons | VL proxy coverage rate, % | VL suppression rate, % | |||
|
Overall
|
2,109,749/8,806,300
|
24
|
80
|
14,875,130/18,573,406
|
80
|
95
|
233
|
19
|
|
Age group, yrs (2017–2022)
| ||||||||
| <10 |
147,143/313,426 |
47 |
67 |
249,530/314,058 |
79 |
84 |
68 |
25 |
| 10–19 |
240,705/496,053 |
49 |
68 |
620,686/729,305 |
85 |
88 |
73 |
29 |
| ≥20 |
3,649,299/8,403,258 |
43 |
86 |
13,941,086/17,202,330 |
81 |
96 |
88 |
12 |
| Unknown*** |
249,150/2,832,066 |
9 |
88 |
63,828/327,713 |
19 |
94 |
111 |
7 |
|
Sex††† (2017–2022)
| ||||||||
| Female |
2,760,201/7,695,526 |
36 |
86 |
9,768,760/12,034,211 |
81 |
95 |
125 |
10 |
| Male |
1,339,638/4,029,411 |
33 |
84 |
5,106,370/6,539,195 |
78 |
95 |
136 |
13 |
|
Pregnant and breastfeeding women with HIV infection§§§ (2017–2022)
|
|
|||||||
| Pregnant women |
80,652/438,315 |
18 |
95 |
150,818/487,608 |
31 |
92 |
72 |
−3 |
| Breastfeeding women |
82,255 |
NA |
85 |
399,082 |
NA |
94 |
— |
11 |
|
Key populations (2020–2022)
| ||||||||
| Female sex workers |
58,378/83,095 |
70 |
93 |
199,435/233,652 |
85 |
97 |
21 |
4 |
| Men who have sex with men |
51,317/79,983 |
64 |
94 |
165,352/210,926 |
78 |
97 |
22 |
3 |
| Persons in prisons and other enclosed settings |
18,605/24,821 |
75 |
93 |
22,836/39,805 |
57 |
93 |
–24 |
0 |
| Persons who inject drugs |
33,716/54,394 |
62 |
93 |
79,822/96,228 |
83 |
96 |
34 |
3 |
| Transgender persons | 2,352/3,328 | 71 | 89 | 7,120/10,700 | 67 | 96 | −6 | 8 |
Abbreviations: ART = antiretroviral therapy; NA = not applicable; PEPFAR = U.S. President’s Emergency Plan for AIDS Relief; VL = viral load.
* VL test result documented in the patient record or laboratory information system.
† Proxy VL coverage rate was calculated as the percentage of persons with HIV infection who received ART for ≥6 months with documented receipt of a VL test within the preceding 12 months.
§ VL suppression was defined as <1,000 HIV copies per mL of blood; suppression rate was calculated as the number of persons with HIV infection with VL suppression among those who received a VL test.
¶ Each characteristic was calculated using data from the end of the fiscal year from which they were available to the end of fiscal year 2022.
** The year of comparison for each group varied based on the quality and availability of data for analyses and is indicated in the row parentheses.
†† Eligible persons are those who have received ART for ≥6 months, derived from the number of persons receiving PEPFAR-supported ART during the two preceding quarters.
§§ Calculated as ([VL coverage 2022 − VL coverage baseline]/VL coverage baseline) * 100.
¶¶ Calculated as ([VL suppression 2022 − VL suppression baseline]/VL suppression baseline) * 100.
*** The value for age unknown includes 327,713 persons who received ART and were eligible for a VL test, reported in aggregate age groups only (i.e., <15 years and ≥15 years). Because of the proxy nature of the indicator, data reporting discrepancies for age group (<15 years and ≥15 years versus age disaggregates in ≤5-year age bands) might be observed.
††† PEPFAR indicators are disaggregated by biologic sex (male or female), where applicable.
§§§ The number of breastfeeding women receiving ART is not reported in PEPFAR monitoring, evaluation, and reporting.